Insight Molecular Diagnostics Inc. Asset Resilience Ratio
Insight Molecular Diagnostics Inc. asset resilience ratio. Insight Molecular Diagnostics Inc. (IMDX) has an Asset Resilience Ratio of 0.54% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IMDX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Insight Molecular Diagnostics Inc. (2013–2023)
Asset resilience ratio of Insight Molecular Diagnostics Inc. from 2013 to 2023. This chart shows how Insight Molecular Diagnostics Inc.'s Asset Resilience Ratio has changed over time. See Insight Molecular Diagnostics Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Insight Molecular Diagnostics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Insight Molecular Diagnostics Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $441.00K | 0.54% |
| Total Liquid Assets | $441.00K | 0.54% |
Asset Resilience Insights
- Limited Liquidity: Insight Molecular Diagnostics Inc. maintains only 0.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Insight Molecular Diagnostics Inc. Industry Peers by Asset Resilience Ratio
Compare Insight Molecular Diagnostics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
BioPorto
CO:BIOPOR |
Diagnostics & Research | 55.77% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
Insight Molecular Diagnostics Inc. Asset Resilience Ratio by Year (2013–2023)
Insight Molecular Diagnostics Inc. asset resilience ratio by year from 2013 to 2023. The table below shows the annual Asset Resilience Ratio data for Insight Molecular Diagnostics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $74.89 Million | -- |
| 2022-12-31 | 0.43% | $433.00K | $100.09 Million | -0.13pp |
| 2021-12-31 | 0.57% | $904.00K | $159.56 Million | -0.65pp |
| 2020-12-31 | 1.22% | $675.00K | $55.42 Million | +0.27pp |
| 2019-12-31 | 0.95% | $379.00K | $39.86 Million | -3.55pp |
| 2018-12-31 | 4.50% | $428.00K | $9.52 Million | -2.94pp |
| 2017-12-31 | 7.44% | $760.00K | $10.22 Million | -8.04pp |
| 2016-12-31 | 15.48% | $2.24 Million | $14.45 Million | -4.47pp |
| 2015-12-31 | 19.96% | $2.54 Million | $12.73 Million | -31.65pp |
| 2014-12-31 | 51.60% | $3.28 Million | $6.36 Million | -4.27pp |
| 2013-12-31 | 55.87% | $4.63 Million | $8.29 Million | -- |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more